Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q4 FY22 results · Jan–Mar 2022
Gufic Biosciences reported revenue from operations of ₹162.19 crore (up 22.9% from Q4 FY21) and net profit of ₹20.26 crore (up 57.5% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a standalone basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 162.19 | 131.93 | +22.9% | 172.07 | −5.7% |
| Other income | 0.04 | 0.66 | −93.8% | 1.53 | −97.3% |
| Total income | 162.23 | 132.58 | +22.4% | 173.60 | −6.5% |
| Profit before tax | 26.18 | 17.05 | +53.5% | 28.73 | −8.9% |
| Net profit for the period | 20.26 | 12.87 | +57.5% | 21.03 | −3.7% |
| EPS, basic (₹) | 2.09 | 1.33 | +57.1% | 2.17 | −3.7% |
| Net margin (%) | 12.5 | 9.8 | 12.2 |
Standalone
- Filed with BSE
- 24 May 2022, 14:32 IST
- Board meeting
- 20 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE